J. Kim, Daniel Chen, Daniel Chen (2016)
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).Annals of oncology : official journal of the European Society for Medical Oncology, 27 8
O. Akbari, Peter Stock, A. Singh, V. Lombardi, W. Lee, G. Freeman, A. Sharpe, D. Umetsu, R. DeKruyff (2010)
PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directionsMucosal Immunology, 3
Koichiro Matsumoto, S. Fukuyama, Miyuki Eguchi-Tsuda, T. Nakano, Takafumi Matsumoto, M. Matsumura, Atsushi Moriwaki, Keiko Kan-o, Y. Wada, H. Yagita, T. Shin, D. Pardoll, Rirprajak Patcharee, M. Azuma, Y. Nakanishi, H. Inoue (2008)
B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma.Biochemical and biophysical research communications, 365 1
A. Rittmeyer, D. Smith, J. Vansteenkiste, L. Fehrenbacher, K. Park, J. Mazières, A. Artal-Cortes, C. Lewanski, F. Braiteh, J. Yi, P. He, W. Zou, D. Waterkamp, M. Ballinger, Ds Chen, A. Sandler, AI Spira (2016)
Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs. docetaxel in 2L/3L NSCLC (POPLAR)Pneumologie, 71
L. Fehrenbacher, A. Spira, M. Ballinger, M. Kowanetz, J. Vansteenkiste, J. Mazières, Keunchil Park, David Smith, A. Artal-Cortes, C. Lewanski, F. Braiteh, D. Waterkamp, P. He, W. Zou, Daniel Chen, J. Yi, A. Sandler, A. Rittmeyer (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialThe Lancet, 387
Daniel Chen, B. Irving, Stephen Hodi (2012)
Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1Clinical Cancer Research, 18
R. Herbst, P. Baas, Dong-Wan Kim, E. Felip, J. Pérez-Gracia, Ji-Youn Han, J. Molina, Joo‐Hang Kim, C. Arvis, M. Ahn, M. Majem, M. Fidler, G. Castro, M. Garrido, G. Lubiniecki, Shentu Yue, E. Im, M. Dolled-Filhart, E. Garon (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 387
A. Paterson, Keturah Brown, M. Keir, V. Vanguri, L. Riella, A. Chandraker, M. Sayegh, B. Blazar, G. Freeman, A. Sharpe (2011)
The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In VivoThe Journal of Immunology, 187
L. Horn, D. Spigel, S. Gettinger, S. Antonia, M. Gordon, R. Herbst, L. Sequist, C. Chappey, M. Kowanetz, A. Sandler, J. Soria (2015)
Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study.Journal of Clinical Oncology, 33
Jang-June Park, R. Omiya, Y. Matsumura, Yukimi Sakoda, Atsuo Kuramasu, M. Augustine, Sheng Yao, Fumihiko Tsushima, H. Narazaki, Sudarshan Anand, Yingjia Liu, S. Strome, Lieping Chen, K. Tamada (2010)
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance.Blood, 116 8
J. Wolchok, A. Hoos, S. O'Day, J. Weber, O. Hamid, C. Lebbé, M. Maio, Michael Binder, O. Bohnsack, G. Nichol, R. Humphrey, Stephen Hodi (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 15
T. Stinchcombe, M. Socinski (2008)
Considerations for second-line therapy of non-small cell lung cancer.The oncologist, 13 Suppl 1
Smith (2016)
Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR)J Clin Oncol, 34
M. Butte, M. Keir, T. Phamduy, A. Sharpe, G. Freeman (2007)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.Immunity, 27 1
Daniel Chen, I. Mellman (2013)
Oncology meets immunology: the cancer-immunity cycle.Immunity, 39 1
Jun Yang, L. Riella, S. Chock, Tao Liu, Xiaozhi Zhao, Xueli Yuan, A. Paterson, Toshihiko Watanabe, V. Vanguri, H. Yagita, M. Azuma, B. Blazar, G. Freeman, S. Rodig, A. Sharpe, A. Chandraker, M. Sayegh (2011)
The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In VivoThe Journal of Immunology, 187
Roy Herbst, J. Soria, M. Kowanetz, G. Fine, O. Hamid, M. Gordon, Jeffery Sosman, David McDermott, J. Powderly, S. Gettinger, H. Kohrt, L. Horn, Donald Lawrence, S. Rost, M. Leabman, Yuanyuan Xiao, A. Mokatrin, H. Koeppen, P. Hegde, I. Mellman, Daniel Chen, F. Hodi (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 515
H. Borghaei, L. Paz-Ares, L. Horn, D. Spigel, M. Steins, N. Ready, L. Chow, E. Vokes, E. Felip, E. Holgado, F. Barlesi, M. Kohlhäufl, O. Arrieta, M. Burgio, J. Fayette, H. Léna, E. Poddubskaya, D. Gerber, S. Gettinger, C. Rudin, N. Rizvi, L. Crinò, G. Blumenschein, S. Antonia, C. Dorange, C. Harbison, F. Finckenstein, J. Brahmer (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.The New England journal of medicine, 373 17
J. Brahmer, K. Reckamp, P. Baas, L. Crinò, W. Eberhardt, E. Poddubskaya, S. Antonia, A. Płużański, E. Vokes, E. Holgado, D. Waterhouse, N. Ready, J. Gainor, O. Frontera, L. Havel, M. Steins, M. Garassino, J. Aerts, M. Dómine, L. Paz-Ares, M. Reck, C. Baudelet, C. Harbison, B. Lestini, D. Spigel (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.The New England journal of medicine, 373 2
T. Powles, J. Eder, G. Fine, F. Braiteh, Y. Loriot, C. Cruz, J. Bellmunt, H. Burris, D. Petrylak, S. Teng, Xiao-dong Shen, Z. Boyd, P. Hegde, Daniel Chen, N. Vogelzang (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature, 515
D. Gandara, M. Redman, F. Hirsch (2016)
Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials.JAMA oncology, 2 3
W. Zou, Lieping Chen (2008)
Inhibitory B7-family molecules in the tumour microenvironmentNature Reviews Immunology, 8
The Lancet – Unpaywall
Published: Jan 1, 2017
Access the full text.
Sign up today, get DeepDyve free for 14 days.